Precision BioSciences gets FDA orphan drug designations for DMD treatment

Investing.com -- Precision BioSciences (NASDAQ: DTIL) has received FDA Orphan Drug Designations for its nuclease treatments targeting Duchenne muscular dystrophy.

The designations were granted for the company's adeno-associated virus serotype 9-delivered DMD19-20L.431 and DMD35-36L.457 nucleases, which are being developed for the treatment of Duchenne muscular dystrophy.

Orphan Drug Designation is given to drugs and biologics intended for the treatment, diagnosis, or prevention of rare diseases that affect fewer than 200,000 people in the United States. This status provides certain benefits to drug developers, including tax credits for qualified clinical trials and potential market exclusivity.

Duchenne muscular dystrophy is a rare genetic disorder characterized by progressive muscle degeneration and weakness due to alterations in a protein called dystrophin that helps keep muscle cells intact.

You May Also Be Interested In

• FDA grants Beyond Air's LungFit GO breakthrough device status for lung disease
• Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
• EPAM Systems rises in premarket as activist reportedly takes stake